Clinical research of Huatuozaizao pill on angina pectoris of conorary heart disease

Objective Clinical observation of Huatuozaizao pill on angina pectoris of conorary heart disease. Methods 582 patients with angina pectoris of conorary heart disease were randomly divided into treatment group (n=388) and control group (n=194). Patients in the treatment group were administrated Huatuozaizao pill and patients in the control group were given Diaoxinxuekang. 30 days was a treatment period and the therapeutic effect was observed after two periods in both groups. Results The total effective rate of clinical symptom of angina pectoris in the treatment group and the control group were 88.81% and 64.95% respectively(P0.01) and the total effective rate of electrocardiogram were 78.35% and 52.57% respectively(P0.05). Compared with pre-treatment, complete blood viscosity, plasma viscosity, erythrocyte aggregation index, thrombocyte aggregation rate and thrombocyte adhesion rate were significantly decreased (P0.05). Serum total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C) were significantly reduced (P0.01, P0.05) and LDL-C in the control group was significantly elevated (P0.05). Compared with the control group, there was a significant difference of thromobocyte aggreagation rate in the treatment group (P0.05). Conclusion Huatuozaizao pill has a better effect on improving angina pectoris symptom, ischemic electrocardiogram and hemodynamics. It also can decrease TC and LDL-C and arteriosclerosis index.